NeuroBo Pharmaceuticals (NRBO) Earnings Date, Estimates & Call Transcripts $2.67 +0.10 (+3.89%) (As of 11/1/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NeuroBo Pharmaceuticals Latest Earnings SummaryUpcoming Q3 Earnings DateNov. 11EstimatedActual EPS (Aug. 14) -$1.85 Missed By -$0.47 Consensus EPS (Aug. 14) -$1.38 NeuroBo Pharmaceuticals released Q2 2024 earnings on August 14, 2024, reporting an EPS of -$1.85, which missed the consensus estimate of -$1.38 by $0.47. With a trailing EPS of $0.00, NeuroBo Pharmaceuticals' earnings are expected to grow next year, from ($4.39) to ($1.67) per share. NRBO Upcoming EarningsNeuroBo Pharmaceuticals' next earnings date is estimated for Monday, November 11, 2024, based off prior year's reporting schedules. Get NeuroBo Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeuroBo Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNRBO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NRBO Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. NeuroBo Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.95-$0.95-$0.95Q2 20241-$1.38-$1.38-$1.38Q3 20241-$1.38-$1.38-$1.38Q4 20241-$1.38-$1.38-$1.38FY 20244($5.09)($5.09)($5.09) NeuroBo Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/11/2024(Estimated)------- 8/14/2024Q2 2024-$1.38-$1.85 -$0.47-$1.85--5/9/2024Q1 2024-$0.95-$1.32 -$0.37-$1.32--11/13/2023Q3 2023--$0.72 -$0.72-$0.09--8/9/2023Q2 2023--$0.16 -$0.16-$0.02--5/12/2023Q1 2023--$0.48 -$0.48-$0.06--11/14/2022Q3 2022-$40.88-$28.00+$12.88-$3.50-- Get the Latest News and Ratings for NRBO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. NeuroBo Pharmaceuticals Earnings - Frequently Asked Questions When is NeuroBo Pharmaceuticals's earnings date? NeuroBo Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 11th, 2024 based off last year's report dates. Learn more on NRBO's earnings history. Did NeuroBo Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, NeuroBo Pharmaceuticals (NASDAQ:NRBO) missed the analysts' consensus estimate of ($1.38) by $0.47 with a reported earnings per share (EPS) of ($1.85). Learn more on analysts' earnings estimate vs. NRBO's actual earnings. How much profit does NeuroBo Pharmaceuticals generate each year? NeuroBo Pharmaceuticals (NASDAQ:NRBO) has a recorded net income of -$12.47 million. NRBO has generated $0.00 earnings per share over the last four quarters. What is NeuroBo Pharmaceuticals's EPS forecast for next year? NeuroBo Pharmaceuticals's earnings are expected to grow from ($4.39) per share to ($1.67) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies GLMD Earnings ORMP Earnings IFRX Earnings ONCY Earnings ALRN Earnings PPBT Earnings VIRI Earnings MNOV Earnings IOBT Earnings PMVP Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to RunBank of America Earnings Uncover Shifts in Consumer Spending Nvidia warning urgent (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. This page (NASDAQ:NRBO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
